As coordinator of the Cancer Genetics Network (CGN) at the National Cancer Institute, I am delighted to have this

opportunity to express my appreciation for your participation in this important research effort, and to update you on

some of the studies underway.

The CGN was created because of concern that important cancer research might not be possible, or might take a

very long time to complete, because the necessary study populations could not be assembled. Today thanks to you,

over 20,000 individuals across the nation have joined the CGN!

With your help, this unique cancer research program is contributing now to our understanding of the causes of

cancer. Some of the studies underway include:

• Early detection of ovarian cancer in high-risk women—Women who have advanced ovarian cancer have higher

levels of a chemical called CA125 in their blood. This study examines whether periodic testing of CA125 levels in

high-risk women could help with the early detection of ovarian cancer.  Early detection can help with more effective

 treatment of cancer and possibly even the prevention of cancer.

• Understanding prostate cancer— Families with two or more relatives with prostate cancer and who were

diagnosed at age 65 years or younger are being recruited into this study. Through this study we hope to learn

about hereditary and environmental factors that may increase a man’s risk for prostate cancer. As a physician

and geneticist I know how powerful the impact of cancer can be on a family, particularly if the cancer could be

caused by a genetic change. Through the support and participation of individuals like you, we are making important

progress towards improving the understanding, screening, diagnosis, and treatment of cancer with the ultimate

aim of preventing the disease.

Thank you.

Carol Kasten-Sportès, MD

Coordinator, Cancer Genetics Network

National Cancer Institute, National Institutes of Health